← FDA DRUG APPROVALS

FDA ANDA · ANDA203306

LANSOPRAZOLE

Sponsor: NATCO

APPLICATION
ANDA203306
TYPE
ANDA
ORIGINAL APPROVAL
2016-01-13
LATEST ACTION
2020-07-21
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Over-the-counter

Products

LANSOPRAZOLEOver-the-counter
LANSOPRAZOLE 15MG · CAPSULE, DELAYED REL PELLETS · ORAL

Approval history

2020-07-21Labeling · Supplement 4 · standardAP
2020-07-21Labeling · Supplement 2 · standardAP
2020-07-21Labeling · Supplement 3 · standardAP
2016-01-13UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →